Two double-blind randomized controlled trials ( RCT ) with Souvenaid of 12 and 24 week duration ( Souvenir I and Souvenir II ) showed that memory performance was improved in drug-nave mild AD patients , whereas no effects on cognition were observed in a 24-week RCT ( S-Connect ) in mild to moderate AD patients using AD medication .